Canaccord Genuity Group Reaffirms "Buy" Rating for Natera (NASDAQ:NTRA)

Key Points

• Canaccord Genuity Group has reaffirmed a "Buy" rating for Natera (NASDAQ:NTRA) with a target price of $200.00, indicating a potential upside of 15.01% from the stock's previous close.
• Several other analysts have issued favorable ratings, including Cowen and Barclays, with target prices ranging from $183.00 to $220.00 for Natera stocks.
• Despite a year-over-year revenue growth of 32.2%, Natera reported a loss of ($0.74) EPS for the last quarter, missing expectations of ($0.60).

Natera (NASDAQ:NTRA - Get Free Report)'s stock had its "buy" rating restated by research analysts at Canaccord Genuity Group in a research note issued on Tuesday,Benzinga reports. They currently have a $200.00 target price on the medical research company's stock. Canaccord Genuity Group's price target indicates a potential upside of 15.01% from the stock's previous close.

Several other equities research analysts also recently commented on the company. Cowen reissued a "buy" rating on shares of Natera in a report on Friday, August 8th. Barclays reaffirmed an "overweight" rating and set a $210.00 price target (up from $190.00) on shares of Natera in a report on Friday, August 8th. Piper Sandler reaffirmed an "overweight" rating and set a $220.00 price target (up from $210.00) on shares of Natera in a report on Monday, August 11th. Stephens reissued an "overweight" rating and issued a $183.00 target price on shares of Natera in a report on Friday, August 15th. Finally, Morgan Stanley restated an "overweight" rating and issued a $195.00 price target on shares of Natera in a research report on Sunday, August 10th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $194.06.

Natera Stock Down 0.2%

Shares of NTRA traded down $0.27 during mid-day trading on Tuesday, hitting $173.90. 52,492 shares of the company's stock traded hands, compared to its average volume of 1,427,463. Natera has a 1 year low of $117.27 and a 1 year high of $183.00. The firm has a market capitalization of $23.87 billion, a P/E ratio of -90.93 and a beta of 1.74. The business's 50-day moving average price is $165.33 and its 200-day moving average price is $157.54.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The firm had revenue of $546.60 million during the quarter, compared to analysts' expectations of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.Natera's revenue for the quarter was up 32.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Natera will post -1.49 earnings per share for the current fiscal year.

Insider Buying and Selling at Natera

In other Natera news, insider Solomon Moshkevich sold 3,000 shares of the business's stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $159.99, for a total transaction of $479,970.00. Following the sale, the insider owned 117,559 shares in the company, valued at approximately $18,808,264.41. The trade was a 2.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Michael Burkes Brophy sold 2,491 shares of the business's stock in a transaction dated Tuesday, September 30th. The shares were sold at an average price of $162.05, for a total value of $403,666.55. Following the sale, the chief financial officer owned 69,189 shares in the company, valued at approximately $11,212,077.45. The trade was a 3.48% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 72,464 shares of company stock worth $10,963,125. 5.63% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Bank of Jackson Hole Trust purchased a new position in Natera in the first quarter valued at $29,000. Hilltop National Bank acquired a new stake in Natera in the second quarter valued at $33,000. Oliver Lagore Vanvalin Investment Group acquired a new stake in Natera in the second quarter valued at $36,000. Rakuten Securities Inc. raised its stake in Natera by 117.8% in the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock valued at $31,000 after buying an additional 119 shares in the last quarter. Finally, Sound Income Strategies LLC raised its stake in Natera by 95.7% in the third quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company's stock valued at $39,000 after buying an additional 110 shares in the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.